Trial Profile
Phase I Study of Tolerance and Pharmacokinetics of TQB2450 Injection
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 13 Mar 2018 New trial record